Search research articles
Contact Us
Filters
Showing results (71-80 of 108) with videos related to
Page
of 11
Sort By:
JCO Global Oncology
|
April 22, 2020
Lack of Targetable FGFR2 Fusions in Endemic Fluke-Associated Cholangiocarcinoma
Sarinya Kongpetch, Apinya Jusakul, Jing Quan Lim, et al.
Liver Cancer
|
September 26, 2022
Systemic Treatment of Advanced Unresectable Hepatocellular Carcinoma after First-Line Therapy: Expert Recommendations from Hong Kong, Singapore, and Taiwan
Thomas Yau, David Tai, Stephen Lam Chan, et al.
Hepatology International
|
July 24, 2015
Survival and pattern of tumor progression with yttrium-90 microsphere radioembolization in predominantly hepatitis B Asian patients with hepatocellular carcinoma
Andrew Yu-Keat Khor, Ying Toh, John Carson Allen, et al.
Asia-Pacific Journal of Clinical Oncology
|
November 27, 2024
Impact of Antibiotics and Chronic Medications on Efficacy of Immune Checkpoint Inhibitors in Patients With Hepatocellular Carcinoma
Kennedy Yao Yi Ng, Albert Eng Keong Teo, Sze Huey Tan, et al.
Plos One
|
May 14, 2015
Correction: The Singapore Liver Cancer Recurrence (SLICER) Score for Relapse Prediction in Patients with Surgically Resected Hepatocellular Carcinoma
Soo Fan Ang, Elizabeth Shu-Hui Ng, Huihua Li, et al.
Plos One
|
April 2, 2015
The Singapore Liver Cancer Recurrence (SLICER) Score for relapse prediction in patients with surgically resected hepatocellular carcinoma
Soo Fan Ang, Elizabeth Shu-Hui Ng, Huihua Li, et al.
Asia-Pacific Journal of Clinical Oncology
|
November 19, 2019
What is the value of third-line chemotherapy in advanced gastroesophageal cancer? A 5-year retrospective analysis at a single center
Justina Yick Ching Lam, Su Pin Choo, David Wai-Meng Tai, et al.
BMC Cancer
|
November 9, 2016
Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial
Mihir Gandhi, Su Pin Choo, Choon Hua Thng, et al.
Lancet (London, England)
|
April 25, 2017
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B El-Khoueiry, Bruno Sangro, Thomas Yau, et al.
NPJ Precision Oncology
|
November 13, 2025
High clinical actionability of a pan-cancer tissue-based combined DNA and RNA next generation sequencing assay in a diverse Asian population
Jing Yi Lee, Aya El Helali, Donavan Jia Jie Tan, et al.
Page
of 11
Search research articles
Search
Showing results (71-80 of 108) with videos related to
Sort By:
Page
of 11
JCO Global Oncology
|
April 22, 2020
Lack of Targetable FGFR2 Fusions in Endemic Fluke-Associated Cholangiocarcinoma
Sarinya Kongpetch, Apinya Jusakul, Jing Quan Lim, et al.
Liver Cancer
|
September 26, 2022
Systemic Treatment of Advanced Unresectable Hepatocellular Carcinoma after First-Line Therapy: Expert Recommendations from Hong Kong, Singapore, and Taiwan
Thomas Yau, David Tai, Stephen Lam Chan, et al.
Hepatology International
|
July 24, 2015
Survival and pattern of tumor progression with yttrium-90 microsphere radioembolization in predominantly hepatitis B Asian patients with hepatocellular carcinoma
Andrew Yu-Keat Khor, Ying Toh, John Carson Allen, et al.
Asia-Pacific Journal of Clinical Oncology
|
November 27, 2024
Impact of Antibiotics and Chronic Medications on Efficacy of Immune Checkpoint Inhibitors in Patients With Hepatocellular Carcinoma
Kennedy Yao Yi Ng, Albert Eng Keong Teo, Sze Huey Tan, et al.
Plos One
|
May 14, 2015
Correction: The Singapore Liver Cancer Recurrence (SLICER) Score for Relapse Prediction in Patients with Surgically Resected Hepatocellular Carcinoma
Soo Fan Ang, Elizabeth Shu-Hui Ng, Huihua Li, et al.
Plos One
|
April 2, 2015
The Singapore Liver Cancer Recurrence (SLICER) Score for relapse prediction in patients with surgically resected hepatocellular carcinoma
Soo Fan Ang, Elizabeth Shu-Hui Ng, Huihua Li, et al.
Asia-Pacific Journal of Clinical Oncology
|
November 19, 2019
What is the value of third-line chemotherapy in advanced gastroesophageal cancer? A 5-year retrospective analysis at a single center
Justina Yick Ching Lam, Su Pin Choo, David Wai-Meng Tai, et al.
BMC Cancer
|
November 9, 2016
Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial
Mihir Gandhi, Su Pin Choo, Choon Hua Thng, et al.
Lancet (London, England)
|
April 25, 2017
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B El-Khoueiry, Bruno Sangro, Thomas Yau, et al.
NPJ Precision Oncology
|
November 13, 2025
High clinical actionability of a pan-cancer tissue-based combined DNA and RNA next generation sequencing assay in a diverse Asian population
Jing Yi Lee, Aya El Helali, Donavan Jia Jie Tan, et al.
Page
of 11